Two hours into trading, Citigroup (NYSE: C ) is up 0.8%, riding the market wave of reassuring -- or at the very least not terrifying -- congressional testimony from Federal Reserve Chairman Ben Bernanke. Monday's positive second-quarter earnings report isn't hurting the stock's performance today either.
The Great Oz has spoken
Bernanke is testifying on monetary policy today before the House Committee on Financial Services; tomorrow he'll do the same before the Senate banking committee. Most on the minds of investors is the fate of quantitative easing, which the markets have come to depend on over the last four years, at least psychologically.
So far, Bernanke's comments seem to indicate that the Fed remains on course to begin tapering QE later this year, so long as U.S. economic data remains positive. But at the same time, the central bank believes the economy is clearly not where it should be -- thus indicating the continuation of accommodative monetary policy.
Best Small Cap Stocks To Buy For 2015: Homeowners Choice Inc.(HCII)
Homeowners Choice, Inc., an insurance holding company, provides property and casualty insurance in Florida. The company provides property and casualty homeowners? insurance, condominium owners? insurance, and tenants? insurance to individuals owning property. It serves approximately 59,500 policyholders primarily through independent agents. The company was founded in 2006 and is headquartered in Tampa, Florida.
Advisors' Opinion:- [By CRWE]
Homeowners Choice, Inc. (Nasdaq:HCII), a Florida-based insurance holding company, reported that its board of directors has declared cash dividends of 5.833 cents per share on its Series A Cumulative Redeemable Preferred Stock (“HCIIP”) for the months ending September 30, October 31 and November 30, 2012.
Top Managed Healthcare Companies To Own For 2014: NiSource Inc (NI)
NiSource Inc. (NiSource), incorporated on March 29, 2000, is an energy holding company whose subsidiaries provide natural gas, electricity and other products and services to approximately 3.8 million customers located within a corridor that runs from the Gulf Coast through the Midwest to New England. NiSource operates in three business segments: Gas Distribution Operations; Gas Transmission and Storage Operations, and Electric Operations. NiSource�� principal subsidiaries include Columbia Energy Group (Columbia), a vertically-integrated natural gas distribution, transmission and storage holding company whose subsidiaries provide service to customers in the Midwest, the Mid-Atlantic and the Northeast; Northern Indiana Public Service Company (Northern Indiana), a vertically-integrated gas and electric company providing service to customers in northern Indiana, and Bay State Gas Company (Columbia of Massachusetts), a natural gas distribution company serving customers in Massachusetts.
NiSource Finance Corporation (NiSource Finance) is a 100% owned, consolidated finance subsidiary of NiSource. NiSource Finance engages in financing activities to raise funds for the business operations of NiSource and its subsidiaries.
Gas Distribution Operations
NiSource�� natural gas distribution operations serve more than 3.3 million customers in seven states and operate approximately 58 thousand miles of pipeline. Through its wholly owned subsidiary, Columbia, NiSource owns five distribution subsidiaries that provide natural gas to approximately 2.2 million residential, commercial and industrial customers in Ohio, Pennsylvania, Virginia, Kentucky, and Maryland. NiSource also distributes natural gas to approximately 795 thousand customers in northern Indiana. Additionally, NiSource�� subsidiary, Columbia Gas of Massachusetts, distributes natural gas to approximately 298 thousand customers in Massachusetts.
Gas Transmission and Storage Operations
NiSou! rce�� Gas Transmission and Storage Operations subsidiaries own and operate approximately 15,000 miles of pipeline and operate a natural gas storage system capable of storing approximately 639 billion cubic feet of natural gas. Through its subsidiaries, Columbia Gas Transmission L.L.C. (Columbia Transmission), Columbia Gulf Transmission Company (Columbia Gulf) and Crossroads Pipeline Company (Crossroads Pipeline), NiSource owns and operates an interstate pipeline network extending from the Gulf of Mexico to New York and the eastern seaboard. Together, these companies serve customers in 16 northeastern, mid-Atlantic, midwestern and southern states and the District of Columbia. NiSource Midstream Services is an unregulated business that is a provider of midstream services, including gathering, treating, conditioning, processing, compression and liquids handling, as well as managing mineral rights positions in the Marcellus and Utica shale areas.
The Gas Transmission and Storage Operations subsidiaries are also engaged in two joint ventures, Millennium Pipeline Company, L.L.C. (Millennium) and Hardy Storage Company, L.L.C. (Hardy Storage). Millennium Pipeline, which includes 252 miles of 30-inch-diameter pipe across New York�� Southern Tier and lower Hudson Valley, has the capability to transport up to 525,400 dekatherm per day of natural gas to markets along its route, as well as to the New York City markets through its pipeline interconnections. Millennium is jointly owned by affiliates of NiSource, DTE Energy and National Grid. Hardy Storage, which consists of underground natural gas storage facilities in West Virginia, has a working storage capacity of 12 billion cubic feet and the ability to deliver 176,000 dekatherm of natural gas per day. Hardy Storage is a joint venture of subsidiaries of Columbia Transmission and Piedmont Natural Gas Company, Inc. (Piedmont).
Electric Operations
NiSource generates, transmits and distributes electricity through its subsidia! ry Northe! rn Indiana Public Service Company (Northern Indiana) to approximately 458 thousand customers in 20 counties in the northern part of Indiana and engages in electric wholesale and transmission transactions. Northern Indiana operates three coal-fired electric generating stations. The three operating facilities have a net capability of 2,574 megawatts. Northern Indiana also owns and operates Sugar Creek, a Combined Cycle Gas Turbine (CCGT) plant with a 535 megawatts capacity rating, four gas-fired generating units located at Northern Indiana�� coal-fired electric generating stations with a net capability of 203 megawatts and two hydroelectric generating plants with a net capability of 10 megawatts. These facilities provide for a total system operating net capability of 3,322 megawatts. Northern Indiana�� transmission system, with voltages from 69,000 to 345,000 volts, consists of 2,797 circuit miles. Northern Indiana is interconnected with five neighboring electric utilities.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on NiSource (NYSE: NI ) , whose recent revenue and earnings are plotted below. - [By David Dittman]
Answer: I like Northeast Utilities (NYSE: NU), Brookfield Renewable Energy Partners LP (TSX: BEP-U, NYSE: BEP), Pembina Pipeline Corp (TSX: PPL, NYSE: PBA), Xcel Energy Inc (NYSE: XEL) and NiSource Inc (NYSE: NI).
- [By Garrett Cook]
In trading on Friday, utilities shares were relative leaders, up on the day by about 0.27 percent. Top gainers in the sector included Enbridge (NYSE: ENB), up 2.2 percent, and NiSource (NYSE: NI), up 1.6 percent.
Top Managed Healthcare Companies To Own For 2014: Liberty Global Inc.(LBTYA)
Liberty Global, Inc. provides video, broadband Internet, and telephony services primarily in Europe and Chile. The company offers broadband services over cable distribution systems, including video, broadband Internet, and telephony; and video services through direct-to-home satellite, or through multichannel multipoint distribution systems. Its analog video services comprise basic and expanded basic programming; and digital cable services include basic and premium programming, digital video recorders, and high definition programming, as well as pay-per-view programming, such as video-on-demand and near video-on-demand. In addition, the company offers voice-over-Internet-protocol and circuit-switched telephony services, as well as mobile telephony services using third-party networks. Further, it owns programming networks that provide video programming channels to multi-channel distribution systems owned by the company and the third parties. As of December 31, 2011, the com pany owned and operated networks that passed 33,262,100 homes; and served 18,405,500 video subscribers, 8,159,300 broadband Internet subscribers, and 6,225,300 telephony subscribers. Liberty Global, Inc. was founded in 2004 and is based in Englewood, Colorado.
Advisors' Opinion:- [By Sam Robson]
LONDON -- Vodafone� (LSE: VOD ) (NASDAQ: VOD ) �is believed to have increased its offer for Kabel Deutschland following a rival bid from�Liberty Global� (NASDAQ: LBTYA ) .
- [By Sam Robson]
LONDON -- In the latest edition of this long-running story, it has been suggested that�Vodafone� (LSE: VOD ) (NASDAQ: VOD ) could use a substantial amount of the money it would receive from selling its stake in Verizon Wireless to fund a takeover of�Liberty Global� (NASDAQ: LBTYA ) .
Top Managed Healthcare Companies To Own For 2014: Mylan Inc (MYL)
Mylan Inc. (Mylan), incorporated in 1970, is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. The Company operates a specialty business, which is focused on respiratory, allergy and psychiatric therapies. Through Mylan Laboratories Limited, an Indian subsidiary, it manufactures and supply active pharmaceutical ingredient (API) for its own products and pipeline, as well as for third parties. On December 23, 2011, Mylan completed the acquisition of rights to develop, manufacture and commercialize a generic equivalent to GlaxoSmithKline�� Advair Diskus and Seretide Diskus incorporating Pfizer Inc.��, (Pfizer) dry powder inhaler delivery platform (the Respiratory Delivery Platform). In February 2012, Valeant Pharmaceuticals International, Inc. announced that it has completed the divestiture of 1% clindamycin and 5% benzoyl peroxide gel (IDP-111), a generic version of Benzaclin, and 5% fluorouracil cream, (5-FU), an authorized generic of Efudex, to the Company.
As of December 31, 2011, Mylan marketed a global portfolio of approximately 1,100 different products covering a range of therapeutic categories. It offers a range of dosage forms and delivery systems, including oral solids, topicals, liquids and semi-solids. In addition, it focuses on transdermal patches, high potency formulations, injectables, controlled release and respiratory delivery products. Mylan operates in two segments: Generics and Specialty. Its revenues are derived from the sale of generic and branded generic pharmaceuticals, specialty pharmaceuticals and API. Its generic pharmaceutical business is conducted in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA), and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its API business is conducted through Mylan Laboratories Limited, which is included within the Asia Pacific region in its Generi! cs segment. Its specialty pharmaceutical business is conducted by Dey Pharma, L.P. (Dey).
Generics Segment
The Company sales in the United States are derived through its wholly owned subsidiary Mylan Pharmaceuticals Inc. (MPI), its primary United States pharmaceutical research, development, manufacturing, marketing and distribution subsidiary, as well as through Mylan Institutional (MI). MPI�� net revenues are derived from the sale of solid oral dosage and transdermal patch products. MI�� net revenues are derived from the sale of its unit dose and injectable product offerings. In the United States, it has product portfolios consisting of approximately 340 products, of which approximately 305 are in capsule or tablet form in an aggregate of approximately 740 dosage strengths. Included in these totals are approximately 40 extended release products in a total of approximately 105 dosage strengths. Also included in it�� the United States product portfolio are four transdermal patch products in a total of 18 dosage strengths, which are developed and manufactured by Mylan Technologies, Inc. (MTI), its wholly owned transdermal technology subsidiary, and marketed and distributed by MPI.
The Company�� North America revenues also include those generated by its wholly owned subsidiary Mylan Pharmaceuticals ULC (MPC), which markets generic pharmaceuticals in Canada. MPC offers a portfolio of approximately 115 products in an aggregate of approximately 250 dosage strengths. Its generic pharmaceutical sales in EMEA are generated by its wholly owned subsidiaries in Europe, through which it has operations in 21 countries.
In France, through the Company�� subsidiary Mylan S.A.S., it markets a retail portfolio of approximately 215 products in an aggregate of approximately 455 dosage strengths. In Italy, it markets through its subsidiary Mylan S.p.A. a portfolio of approximately 150 products in an aggregate of approximately 285 dosage strengths. In Italy, it h! as market! share, based on value and volume, in the company-branded generic retail prescription market. In Spain, it markets through its subsidiary Mylan Pharmaceuticals S.L. a portfolio of approximately 100 products in an aggregate of approximately 220 dosage strengths. In Germany, it markets through its subsidiary Mylan dura a portfolio of approximately 150 products in an aggregate of approximately 330 dosage strengths. In the United Kingdom, it offers a product portfolio of approximately 175 products in an aggregate of approximately 315 dosage strengths. It markets generic pharmaceuticals in Asia Pacific through subsidiaries in Australia, New Zealand, India, Japan and Taiwan.
In Australia, the Company offers a portfolio of approximately 170 products in an aggregate of approximately 440 dosage strengths. Mylan Seiyaku, its wholly owned Japanese subsidiary, offers a portfolio of more than 380 products in an aggregate of approximately 500 dosage strengths. At Mylan Laboratories Limited, its dosage business produces antiretroviral (ARV) products, which are sold outside of India, and other finished dosage form (FDF) products, which are sold to third parties by other Mylan operations globally. In addition, Mylan Laboratories Limited offers a line of FDF products in the ARV market and manufactures non-ARV FDF products that are marketed by Mylan.
Specialty Segment
The Company�� specialty pharmaceutical business is conducted through Dey. Dey�� portfolio consists of branded specialty injectable, nebulized and transdermal products for life-threatening conditions. Dey�� revenues are derived through the sale of the EpiPen Auto-Injector. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector that has been sold in the United States and internationally.
Advisors' Opinion:- [By Seth Jayson]
Mylan (Nasdaq: MYL ) reported earnings on May 2. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), Mylan missed estimates on revenues and met expectations on earnings per share. - [By Ben Levisohn]
Mylan (MYL) wants to start preparing a generic version of two Celegene (CELG) drugs. Celegene obviously wants to make that as difficult as possible. And now they’re heading to court.
Reuters has the details on Mylan’s lawsuit against Celgene:
In its lawsuit filed in the U.S. District Court in Newark, New Jersey, Mylan accused Celgene of using federal limits on the distribution of Revlimid and Thalomid, which were designed to promote the drugs’ safety, as a pretext to keep generic drug makers from obtaining their own samples…
The lawsuit seeks to force Celgene to sell Mylan enough Revlimid and Thalomid at market prices to allow for bioequivalence testing. It also seeks compensation for Mylan’s inability to sell generic versions of both, and triple damages.
Barclays’ Ying Huang and team believe the odds favor Celgene over Mylan:
It is our understanding that [Celgene] has no obligation to provide samples of Revlimid to generic manufacturers. The Risk Evaluation and Mitigation Strategies (REMS) program required by the FDA for Revlimid also makes it difficult to obtain the product on the open market. Patients and physicians are required under REMS to register in a database administered by�[Celgene] before Revlimid is distributed. We note the REMS program argument has been upheld by the court in previous generic litigation cases.
Shares of Celgene have dropped 4.1% to $137.79 at 2:28 p.m., while Mylan has gained 2.3% to $51.02.
- [By Dan Carroll]
The market has undergone a topsy-turvy second half of 2014; but for investors in leading generic drugmaker Mylan (NASDAQ: MYL ) , the year's brought a bountiful harvest. Mylan's stock has rocketed up more than 20% year to date, with shares vaulting higher by more than 15% in the past month alone.
- [By Rich Bieglmeier]
Mylan, Inc. (MYL) will host a conference call and live webcast Thursday, Oct. 31, 2013, at 10:00 a.m. ET, to review the company's financial results for the third quarter, which ended Sept 30, 2013. Mylan will release its financial results on Oct. 31 before the market opens.
No comments:
Post a Comment